COMPARATIVE EFFICACY OF RISANKIZUMAB AND SECUKINUMAB IN MODERATE TO SEVERE PLAQUE PSORIASIS

E. Tejedor Tejada¹, M. Rodríguez Goicoechea², D. Rubio Calvo³ S. Cano Domínguez³, N. García Gómez², MJ. Barbero Hernández², F. Horno Ureña²

1. Clínica Hospital of Barcelona, 2. Universitary Hospital Complex of Jaén, 3. Andujar's Hospital

Background and importance
The wide range of drugs and mechanisms of action makes the choice of treatment for patients with moderate to severe psoriasis increasingly complex.

Aim and Objectives
Evaluation of effectiveness through indirect comparisons between risankizumab (RIS) (anti-IL23) and secukinumab (SEC) (anti-IL17).

MATERIALS AND METHODS
Multicentre, observational, retrospective study to indirectly compare patients on RIS and SEC
Time: June 2021 - June 2022.

RESULTS
Patients N=111 (60 RIS/ 50 SEC)
Sex: 63.3% men
Average age: RIS 51,1 vs SEC 39,9 years
The biologic PRE-treatments were: Etanercept (31) > Adalimumab (23)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>12 weeks</th>
<th>24 weeks</th>
<th>48 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIS</td>
<td>BSA</td>
<td>11,9</td>
<td>1,6</td>
<td>1,5</td>
</tr>
<tr>
<td></td>
<td>PASI</td>
<td>8,3</td>
<td>1,5</td>
<td>0,7</td>
</tr>
<tr>
<td>SEC</td>
<td>BSA</td>
<td>11,4</td>
<td>2,3</td>
<td>0,7</td>
</tr>
<tr>
<td></td>
<td>PASI</td>
<td>8,6</td>
<td>1,8</td>
<td>0,6</td>
</tr>
</tbody>
</table>

Conclusion and Relevance
Based on data from comparative studies, there is no significant difference between the effectiveness of risankizumab and secukinumab. More studies are needed to define the gold-standard drug.

REFERENCES

Investigator contact: tejedor@clinic.cat